newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic ("PK") result